Eledon Advances Tegoprubart into Phase 3 Kidney Transplant Trial with Strong FDA Backing — Eledon Pharmaceuticals, Inc.

Event summary

Eledon completed a successful End-of-Phase 2 meeting with the FDA, paving the way for a global Phase 3 kidney transplantation trial set to begin in late 2026.
Long-term Phase 2 BESTOW data showed tegoprubart maintained higher kidney function and better patient-reported outcomes compared to tacrolimus.
Islet cell transplantation study achieved 100% insulin independence in all 12 type 1 diabetes patients treated with tegoprubart.
Cash reserves stood at $88.8 million as of June 30, 2026, down from $133.3 million at the end of 2025.

The big picture

Eledon's progress with tegoprubart positions it as a key player in the transplant immunotherapy space, competing against established calcineurin inhibitors like tacrolimus. The successful FDA meeting and compelling clinical data reinforce the drug's potential to improve outcomes across multiple transplant settings, though financial sustainability remains a critical watchpoint given the company's burn rate.

What we're watching

Trial Execution: Whether Eledon can successfully initiate and complete the Phase 3 kidney transplantation trial by late 2026.
Financial Runway: The pace at which Eledon's cash reserves deplete, given current spending levels and anticipated trial costs.
Regulatory Pathways: How the FDA's guidance on tegoprubart's path to market in xenotransplantation could expand its therapeutic potential.